Citeline：2025 ADCs药物的临床转化之路研究报告（英文版）-三个皮匠报告

1、C I T E L I N E.C O MAntibody-drug ConjugatesMagic Bullets Become Reality Magic Bullets Become Reality Expert Series 2025Presented by Heidi Chen,PhDAssociate DirectorResearch and Commercial ServicesBased on white paper byJon Stephens,Associate DirectorArbesa Bela,Senior AnalystAntibody-drug Conjugat

2、es Magic Bullets Become Reality Agenda 3o Introductiono The makeup of ADCso Mechanisms of ADCso Challenges of ADCso Development landscape of ADCso A future beyond cancero Conclusions and Q&AC I T E L I N E.C O MintroductionCancer therapy goes monoclonalCancer is one of the leading causes of death Pr

3、ojection of 16.3million deaths by 2040Traditional treatments fall short Debilitating side effects due to damage to healthy cellsShift to use of monoclonal antibodies(mAbs)Provided targeted tumor-specific treatment Rituximab first mAb launched in 1997Total launched mAbs since 19975143 currently marke

4、ted for cancer treatment Pharmaprojects,Oct 202413443557778810121416182735435159657795111122141020406080100120140160Launched monoclonal antibody(mAb)drugs for cancer 19972024C I T E L I N E.C O MThe makeup of ADCsAntibody Drug Conjugate components7Antibody Acts as a targeted delivery system,guiding

5、the ADC directly towards antigen-expressing tumor cellsLinker Links the antibody and payload moieties Ensures the highly cytotoxic payload remains stably bound to the antibody and thus inert while in the systemic circulation.Payload The cytotoxic molecule responsible for its cancer-killing effect.An

6、tibody selection Use of chimeric and humanized antibodies reduce immunogenic side effects Current ADCs are widely based on immunoglobulin G(IgG),which combines a long half-life with strong antibody-mediated immune effects High specificity to target antigens expressed primarily in tumor cells,but low

Citeline：2025 ADCs药物的临床转化之路研究报告（英文版）（23页）.pdf

相关报告